Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group

Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Davies, Stella M., Borowitz, Michael J., Rosner, Gary L., Ritz, Kristin, Devidas, Meenakshi, Winick, Naomi, Martin, Paul L., Bowman, Paul, Elliott, James, Willman, Cheryl, Das, Soma, Cook, Edwin H., Relling, Mary V.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2008
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2265447/
https://ncbi.nlm.nih.gov/pubmed/18182569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-09-114082
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars